The development and validation of a novel LC-MS/MS method for the simultaneous quantification of Molnupiravir and its metabolite β-d-N4-hydroxycytidine in human plasma and saliva

Amara, Alieu ORCID: 0000-0002-1137-2948, Penchala, Sujan Dilly, Else, Laura, Hale, Colin, FitzGerald, Richard, Walker, Lauren ORCID: 0000-0002-3827-4387, Lyons, Rebecca, Fletcher, Tom and Khoo, Saye ORCID: 0000-0002-2769-0967 (2021) The development and validation of a novel LC-MS/MS method for the simultaneous quantification of Molnupiravir and its metabolite β-d-N4-hydroxycytidine in human plasma and saliva. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 206. 114356-.

Text Final MPV Manuscript - Clean.docx - Author Accepted Manuscript Download (62kB)

Abstract

In light of the recent global pandemic, Molnupiravir (MPV) or EIDD-2801, developed for the treatment of patients with uncomplicated influenza, is now being trialled for the treatment of infections caused by highly pathogenic coronaviruses, including COVID-19. A sensitive LC-MS/MS method was developed and validated for the simultaneous quantification of MPV and its metabolite ß-d-N4-hydroxycytidine (NHC) in human plasma and saliva. The analytes were extracted from the matrices by protein precipitation using acetonitrile. This was followed by drying and subsequently injecting the reconstituted solutions onto the column. Chromatographic separation was achieved using a polar Atlantis C₁₈ column with gradient elution of 1 mM Ammonium acetate in water (pH4.3) and 1 mM Ammonium acetate in acetonitrile. Analyte detection was conducted in negative ionisation mode using SRM. Analysis was performed using stable isotopically labelled (SIL) internal standards (IS). The m/z transitions were: MPV (328.1→126.0), NHC (258.0→125.9) and MPV-SIL (331.0→129.0), NHC-SIL (260.9→128.9). Validation was over a linear range of 2.5-5000 ng/ml for both plasma and saliva. Across four different concentrations, precision and accuracy (intra- and inter-day) were 15%; and recovery of both analytes from plasma and saliva was between 95% and 100% and 65-86% respectively. Clinical pharmacokinetic studies are underway utilising this method for determination of MPV and its metabolite in patients with COVID-19 infection.

Item Type:	Article
Uncontrolled Keywords:	Antiviral therapy, Coronavirus, Molnupiravir, N4-hydroxycytidine, LC-MS/MS, Plasma, Saliva
Divisions:	Faculty of Health and Life Sciences Faculty of Health and Life Sciences > Institute of Systems, Molecular and Integrative Biology
Depositing User:	Symplectic Admin
Date Deposited:	26 Nov 2021 08:37
Last Modified:	17 Oct 2023 20:22
DOI:	10.1016/j.jpba.2021.114356
Related URLs:	Author Publisher
URI:	https://livrepository.liverpool.ac.uk/id/eprint/3143849